1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. Consensus
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
4.780 USD   +14.35%
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE« CTD and AVISE« Lupus
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE« CTD and AVISE« Lupus
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE« CTD and AVISE« Lupus
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Evolution of the average Target Price on EXAGEN INC.
Target Price consensus revisions : last 18 months
Recommendations (Chart) EXAGEN INC.
Analyst Recommendations on EXAGEN INC.
05/13KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating
MT
03/25KeyBanc Adjusts Exagen's Price Target to $20 From $30, Reiterates Overweight Rating
MT
03/23Cowen Adjusts Exagen's Price Target to $16 from $26, Reiterates Outperform Rating
MT
2021KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating
MT
2021EXAGEN : BTIG Adjusts Exagen's Price Target to $20 From $23, Reiterates Buy Rating
MT
2021EXAGEN : Canaccord Genuity Initiates Exagen at Buy Rating With $25 Price Target
MT
2020EXAGEN : KeyBanc Initiates Exagen at Overweight with $32 Price Target
MT
More recommendations
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 4,78 $
Average target price 16,40 $
Spread / Average Target 243%
High Price Target 19,00 $
Spread / Highest target 297%
Low Price Target 13,00 $
Spread / Lowest Target 172%
Consensus detail
Consensus revision (last 18 months)